These May Well Be Euro-Crisis-Immune

Two top-performing biotech stocks could offer major relief from the endless misery of the euro crisis. These speculative issues have the power to defy gravity in the worst markets, because retail traders will drive price action between key research milestones and pronouncements from the Food and Drug Administration. Just keep a calendar close to your desk and get back to the sidelines before a scheduled release triggers a feast or famine response

Let me explain that last line, because it might sound confusing as you ponder new exposure in the group. Many folks think the whole point of owning research-rich, cash-poor biotech stocks is to get a big paycheck when the FDA finally approves a key drug application -- or when a sugar daddy, like Merck (MRK) or Pfizer (PFE), comes along and buys out the company at a sizable premium....521 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.

Read the full story and get access to the Real Money Pro trading floor.

There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.

Already a Subscriber? Please login.

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.